person · Reporting owner

Loh Evan

Disclosed activity across 4 companies

Tapewire entity: 109530
SEC CIK: 0001622680

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALPINE IMMUNE SCIENCES, INC.NVLS · Entity 90802	Director	September 12, 2016	September 14, 2016
Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554	Director	March 01, 2023	March 03, 2023
WINDTREE THERAPEUTICS INC /DE/WINT · Entity 8761	Director	February 03, 2021	February 06, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALPINE IMMUNE SCIENCES, INC.

Report date September 12, 2016 · Filed September 14, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.77 · Expires 2026-09-12	Direct	12,300	Reported balance After 2016-09-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-09-12 · Grant · Acquired 12,300 · Balance 12,300 F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2: The shares shall vest in 12 equal monthly installments commencing on October 12, 2016.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F2: The shares shall vest in 12 equal monthly installments commencing on October 12, 2016.

Eiger BioPharmaceuticals, Inc.

Report date March 01, 2023 · Filed March 03, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2033-02-28	Direct	28,000	Reported balance After 2023-03-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-03-01 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.

WINDTREE THERAPEUTICS INC /DE/

Report date February 03, 2021 · Filed February 06, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2031-02-03	Direct	30,000	Reported balance After 2021-02-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-02-03 · Grant · Acquired 30,000 · Balance 30,000 F1: The stock option shall vest in three equal annual installments beginning on the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option shall vest in three equal annual installments beginning on the first anniversary of the grant date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Paratek Pharmaceuticals, Inc.

Report date September 21, 2023 · Filed September 21, 2023

Section 16 reporting ended · disclosed 2023-09-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2023-09-21 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-09-21 · Disposition to issuer · Disposed 1,069,231 · Balance 258,750 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC. Row 2 · 2023-09-21 · Disposition to issuer · Disposed 258,750 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration, F4: (Continued from Footnote 3) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger. If provided for pursuant to a subscription agreement entered into among the Reporting Person, the Issuer and Resistance TopCo L.P., a Delaware limited partnership ("Topco LP"), the settlement of such Equity Award Consideration may also be made inequity interests of Topco LP.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger").

F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC.

F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration,

F4: (Continued from Footnote 3) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger. If provided for pursuant to a subscription agreement entered into among the Reporting Person, the Issuer and Resistance TopCo L.P., a Delaware limited partnership ("Topco LP"), the settlement of such Equity Award Consideration may also be made inequity interests of Topco LP.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 02, 2018 Filed Oct 4, 2018 20:41 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	55,000	$0.00	$0.00	Disclosure SEC source: 0000904454-18-000642 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,286 F2 · shares: Represents PRSUs granted on August 3, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 2, 2018. These PRSUs will settle in shares of common stock on October 2, 2019, provided that the Reporting Person remains in continuous service with Paratek Pharmaceuticals, Inc. through the settlement date. Read SEC document
October 02, 2018 Filed Oct 4, 2018 20:41 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	32,500	$0.00	$0.00	Disclosure SEC source: 0000904454-18-000642 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,286 F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 2, 2018. Read SEC document
July 02, 2018 Filed Jul 5, 2018 18:46 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	SaleCommon Stock	12,000	$9.97	$119,640.00	Disclosure SEC source: 0000904454-18-000462 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,786 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units, pursuant to Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.93 to $10.03. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. Read SEC document
April 09, 2018 Filed Apr 10, 2018 19:40 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	SaleCommon Stock	8,084	$12.70	$102,666.80	Disclosure SEC source: 0000904454-18-000285 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,786 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of performance-based restricted stock units, pursuant to Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $12.60 to $12.85. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. Read SEC document
April 03, 2018 Filed Apr 5, 2018 18:42 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	19,500	$0.00	$0.00	Disclosure SEC source: 0000904454-18-000277 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,870 F1 · shares: Represents performance-based restricted stock units granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on April 3, 2018. Read SEC document
March 14, 2018 Filed Mar 16, 2018 20:25 UTC	Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $9.50	$0.00	Disclosure SEC source: 0001209191-18-020457 · doc4.xml · derivative · entry 1 Loh Evan · CIK 0001622680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-03-13 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 14, 2018 subject to Reporting Person's continuous service status as of each such date. Read SEC document
February 14, 2018 Filed Feb 16, 2018 16:52 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	58,500	$0.00	$0.00	Disclosure SEC source: 0000904454-18-000185 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,370 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 1/3 of the shares subject to the restricted stock units on December 10, 2018, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
February 05, 2018 Filed Feb 7, 2018 18:23 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	SaleCommon Stock	3,040	$14.22	$43,228.80	Disclosure SEC source: 0000904454-18-000138 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,870 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.43, inclusive. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 15, 2017 Filed Sep 18, 2017 17:33 UTC	Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $11.15	$0.00	Disclosure SEC source: 0001209191-17-053205 · doc4.xml · derivative · entry 1 Loh Evan · CIK 0001622680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-09-15 F1 · derivative.exercise_date: The option vests in equal monthly installments over 36 months measured from September 15, 2017 subject to Reporting Person's continuous service status as of each such date. Read SEC document
July 19, 2017 Filed Jul 21, 2017 16:38 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	Exercise / conversionStock Option (right to buy) · Derivative	39,478	$0.00 Strike: $4.30	$0.00	Disclosure SEC source: 0000904454-17-000529 · edgar.xml · derivative · entry 2 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,479 Underlying: Common Stock · 39,478 shares Expires 2024-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: The Issuer entered into an Agreement and Plan of Merger and Reorganization, dated as of June 30, 2014 (the "Merger Agreement"), by and among the Issuer, Tigris Merger Sub, Inc., Tigris Acquisition Sub, LLC and a Delaware corporation then known as Paratek Pharmaceuticals, Inc. ("Old Paratek"). F3 · derivative.exercise_date: On June 29, 2014, the Reporting Person was granted an option to purchase 1,169,742 shares of the common stock of Old Paratek under Old Paratek's 2014 Equity Incentive Plan at a per share exercise of price of $0.29 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 78,957 shares of the Issuer's common stock at a per share exercise price of $4.30 upon closing of the merger. The option was previously reported on Form 4 filed on November 3, 2014. F4 · derivative.exercise_date: The vesting schedule for this stock option is as follows: 1/48th (2.1%) of the option, or approximately 1,645 shares, vests and becomes exercisable on each of the 48 months commencing on January 1, 2015, subject generally to the Reporting Person's continued employment with the Issuer Read SEC document
July 19, 2017 Filed Jul 21, 2017 16:38 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	Exercise / conversionCommon Stock	39,478	$4.30	$169,755.40	Disclosure SEC source: 0000904454-17-000529 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock acquired from the exercise of a stock option. Read SEC document
July 05, 2017 Filed Jul 6, 2017 17:00 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	SaleCommon Stock	4,351	$23.58	$102,591.36	Disclosure SEC source: 0000904454-17-000503 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,432 F2 · shares: Sale of shares to cover personal income tax obligations upon vesting of performance-based restricted stock units, pursuant to Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.45 to $23.90, inclusive. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document
July 03, 2017 Filed Jul 6, 2017 17:00 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	13,000	$0.00	$0.00	Disclosure SEC source: 0000904454-17-000503 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,783 F1 · shares: Represents performance-based restricted stock units granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on July 3, 2017. Read SEC document
February 06, 2017 Filed Feb 8, 2017 18:35 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	SaleCommon Stock	22	$15.09	$331.98	Disclosure SEC source: 0000904454-17-000135 · edgar.xml · nonDerivative · entry 6 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,783 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan. Read SEC document
February 06, 2017 Filed Feb 8, 2017 18:35 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	SaleCommon Stock	1,082	$15.05	$16,284.10	Disclosure SEC source: 0000904454-17-000135 · edgar.xml · nonDerivative · entry 5 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,805 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan. Read SEC document
February 06, 2017 Filed Feb 8, 2017 18:35 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	SaleCommon Stock	16	$15.08	$241.20	Disclosure SEC source: 0000904454-17-000135 · edgar.xml · nonDerivative · entry 4 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,887 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan. Read SEC document
February 06, 2017 Filed Feb 8, 2017 18:35 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	SaleCommon Stock	1,302	$15.10	$19,660.20	Disclosure SEC source: 0000904454-17-000135 · edgar.xml · nonDerivative · entry 3 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,903 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan. Read SEC document
February 06, 2017 Filed Feb 8, 2017 18:35 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	SaleCommon Stock	668	$15.15	$10,120.20	Disclosure SEC source: 0000904454-17-000135 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,205 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan. Read SEC document
February 06, 2017 Filed Feb 8, 2017 18:35 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	SaleCommon Stock	16	$15.20	$243.20	Disclosure SEC source: 0000904454-17-000135 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,873 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan. Read SEC document
February 02, 2017 Filed Feb 6, 2017 19:13 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantStock Option (right to buy) · Derivative	65,000	$0.00 Strike: $15.10	$0.00	Disclosure SEC source: 0000904454-17-000099 · edgar.xml · derivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-02-01 F1 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: The shares shall vest as to 1/36 of the shares on the one-month anniversary following February 2, 2017 and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service to the Company at each vesting date. Read SEC document
September 12, 2016 Filed Sep 14, 2016 16:16 UTC	ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802	GrantStock Option (Right to Buy) · Derivative	12,300	$0.00 Strike: $7.77	$0.00	Disclosure SEC source: 0001104659-16-144633 · a4.xml · derivative · entry 1 Loh Evan · CIK 0001622680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,300 Underlying: Common Stock · 12,300 shares Expires 2026-09-12 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: The shares shall vest in 12 equal monthly installments commencing on October 12, 2016. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.